Who is sponsoring NCT03203460?

NCT03203460 is sponsored by University of Alberta.

What drugs are being tested in NCT03203460?

Interventions in NCT03203460: High-intensity aerobic interval training (HIIT).

What condition does NCT03203460 study?

NCT03203460 studies Prostate Cancer.

Is NCT03203460 still recruiting?

NCT03203460 is currently completed. Last updated 18 April 2022.

Last reviewed 2022-04-18 · How we verify

NCT03203460: ERASE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exercise During Active Surveillance for Prostate Cancer

Completed NA Last updated 18 April 2022

What this trial tests

NA trial testing High-intensity aerobic interval training (HIIT) in Prostate Cancer in 52 participants. Completed in 31 May 2021.

Timeline

1 July 2018

Primary endpoint
31 May 2020

31 May 2021

Quick facts

Lead sponsor	University of Alberta
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	52
Start date	1 July 2018
Primary completion	31 May 2020
Estimated completion	31 May 2021
Sites	1 location across Canada

Drugs / interventions tested

High-intensity aerobic interval training (HIIT)

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

University of Alberta

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The broad goal of the Exercise During Active Surveillance for Prostate Cancer (ERASE) trial is to examine the effects of exercise in prostate cancer patients undergoing active surveillance.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance: The ERASE Randomized Clinical Trial.
Kang DW, Fairey AS, Boulé NG, Field CJ, et al · · 2021 · cited 73× · PMID 34410322 · DOI 10.1001/jamaoncol.2021.3067
Exercise duRing Active Surveillance for prostatE cancer-the ERASE trial: a study protocol of a phase II randomised controlled trial.
Kang DW, Fairey AS, Boulé NG, Field CJ, et al · · 2019 · cited 11× · PMID 31278095 · DOI 10.1136/bmjopen-2018-026438
Effects of supervised high-intensity interval training on motivational outcomes in men with prostate cancer undergoing active surveillance: results from a randomized controlled trial.
Kang DW, Boulé NG, Field CJ, Fairey AS, et al · · 2022 · cited 5× · PMID 36175907 · DOI 10.1186/s12966-022-01365-2

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other University of Alberta trials

Trials by the same sponsor.

NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03203460 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alberta
Last refreshed: 18 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03203460.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing